↓ Skip to main content

Recent advances on smart glycoconjugate vaccines in infections and cancer

Overview of attention for article published in FEBS Journal, June 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

1 news outlet
12 tweeters


9 Dimensions

Readers on

56 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Recent advances on smart glycoconjugate vaccines in infections and cancer
Published in
FEBS Journal, June 2021
DOI 10.1111/febs.15909
Pubmed ID

Marko Anderluh, Francesco Berti, Anna Bzducha‐Wróbel, Fabrizio Chiodo, Cinzia Colombo, Federica Compostella, Katarzyna Durlik, Xhenti Ferhati, Rikard Holmdahl, Dragana Jovanovic, Wieslaw Kaca, Luigi Lay, Milena Marinovic‐Cincovic, Marco Marradi, Musa Ozil, Laura Polito, Josè Juan Reina, Celso A. Reis, Robert Sackstein, Alba Silipo, Urban Švajger, Ondřej Vaněk, Fumiichiro Yamamoto, Barbara Richichi, Sandra J. Vliet


Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen-specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the Human Immunodeficiency Virus or to induce cellular T cell immunity in the fight against cancer. The recent SARS-CoV-2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan-coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as 'tumor-associated carbohydrate antigens' (TACA). Unfortunately, glycans do not provoke a vigorous immune response and generally serve as T cell-independent antigens, not eliciting protective IgG responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses, and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy.

Twitter Demographics

The data shown below were collected from the profiles of 12 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 56 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 21%
Researcher 8 14%
Student > Bachelor 6 11%
Student > Postgraduate 5 9%
Student > Master 5 9%
Other 8 14%
Unknown 12 21%
Readers by discipline Count As %
Chemistry 11 20%
Biochemistry, Genetics and Molecular Biology 8 14%
Agricultural and Biological Sciences 7 13%
Medicine and Dentistry 6 11%
Nursing and Health Professions 3 5%
Other 5 9%
Unknown 16 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 April 2022.
All research outputs
of 21,011,736 outputs
Outputs from FEBS Journal
of 4,965 outputs
Outputs of similar age
of 338,938 outputs
Outputs of similar age from FEBS Journal
of 98 outputs
Altmetric has tracked 21,011,736 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,965 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,938 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.